The NICE COVID-19 rapid guideline on haematopoietic stem cell transplantation: development, implementation and impact

Kim Orchard, Fiona L Dignan, Julia Lee, Rachel Pearce, Monica Desai, Emma McFarlane, Angela Parkin, Peter Shearn, John A Snowden, Kim Orchard, Fiona L Dignan, Julia Lee, Rachel Pearce, Monica Desai, Emma McFarlane, Angela Parkin, Peter Shearn, John A Snowden

No abstract available

Keywords: COVID-19; SARS-CoV-2; allogeneic; autologous; donor; haematopoietic stem cell transplantation.

Conflict of interest statement

JAS was chair of BMT‐CRG from June 2016–June 2020, and FLD is chair from April 2020. They co‐chaired the BMT‐CRG from April–June 2020. KO was President of BSBMTCT from January 2018 to December 2020, and JS is President from January 2021–December 2022. No other conflicts of interest were declared.

Figures

Fig 1
Fig 1
(A) Day 0 reported autologous HSCT activity in the period 1 January–31 July, comparing monthly totals for 2019 and 2020. P‐values were determined from a linear regression model using monthly data for 2007–2019, assuming normally distributed variation. (B) Day 0 reported allogeneic HSCT activity in the period 1 January–31 July, comparing monthly totals for 2019 and 2020. P‐values were determined from a linear regression model using monthly data for 2007–2019, assuming normally distributed variation. [Colour figure can be viewed at wileyonlinelibrary.com]

References

    1. Chemaly RF, Shah DP, Boeckh MJ. Management of respiratory viral infections in hematopoietic cell transplant recipients and patients with hematologic malignancies. Clin Infect Dis. 2014;59(Suppl 5):S344–S351.
    1. NICE . COVID‐19 rapid guideline: haematopoietic stem cell transplantation [updated 29/07/2020]. Available from:
    1. Ljungman P, Mikulska M, de la Camara R, Basak GW, Chabannon C, Corbacioglu S, et al. The challenge of COVID‐19 and hematopoietic cell transplantation; EBMT recommendations for management of hematopoietic cell transplant recipients, their donors, and patients undergoing CAR T‐cell therapy. Bone Marrow Transplant. 2020;55:2071–6.
    1. BSBMTCT .BSBMT&CT recommendations for the management of adult patients and allogeneic donors during the COVID‐19 (causative agent the SARS‐CoV‐2 virus) outbreak. 2020. [16.05.2020]. Available from:
    1. Ljungman P, Styczynski J, Mikulska M, de la Camara R. CORONAVIRUS DISEASE COVID‐19: EBMT RECOMMENDATIONS [website]. ebmt; 2020. [updated 23 Dec 2020; cited 2020 Dec 27]. Available from:
    1. NICE . Developing NICE guidelines: the manual 2014 [updated 17/07/2020; cited 2020]. Available from:
    1. NICE . Research to access pathway for investigational drugs for COVID‐19 (RAPID‐C19). 2020. Available from:
    1. Lee SJ, Loberiza FR, Antin JH, Kirkpatrick T, Prokop L, Alyea EP, et al. Routine screening for psychosocial distress following hematopoietic stem cell transplantation. Bone Marrow Transplant. 2005;35(1):77–83.
    1. ONS . Office for National Statistics: Impact of the coronavirus pandemic on the mental health of clinically extremely vulnerable people [Web page]. [updated 29/06/2020]. Available from:
    1. Nolan A. Telephone Emotional Support [cited 2020 Dec 27]. Available from:
    1. Willan J, King AJ, Hayes S, Collins GP, Peniket A. Care of haematology patients in a COVID‐19 epidemic. Br J Haematol. 2020;189(2):241–3.
    1. PHE .Protect yourself and others from coronavirus 2020. Available from:
    1. Zhou X, Wang G, Chen L, Meng F, Huang L, Huang L, et al. Clinical characteristics of hematological patients concomitant with COVID‐19. Cancer Sci. 2020;111(9):3379–85.
    1. NICE . NICE guideline on neutropenic sepsis: CG151 2012. Available from:
    1. PHE . COVID‐19: infection prevention and control (IPC) : HM Government UK; 2020. [updated 16/09/2020]. Available from:
    1. Passamonti F, Cattaneo C, Arcaini L, Bruna R, Cavo M, Merli F, et al. Clinical characteristics and risk factors associated with COVID‐19 severity in patients with haematological malignancies in Italy: a retrospective, multicentre, cohort study. Lancet Haematol. 2020;7(10):e737–e745.
    1. Ljungman P, de la Camara R, Mikulska M, Tridello G, Aguado B, Beguin Y, et al. COVID‐19 and stem cell transplantation; results from an EBMT and GETH multicenter prospective survey. EBMT Annual Meeting; 29.08.2020; Madrid.
    1. Shah V, Ko Ko T, Zuckerman M, Vidler J, Sharif S, Mehra V, et al. Poor outcome and prolonged persistence of SARS‐CoV‐2 RNA in COVID‐19 patients with haematological malignancies; King's College Hospital experience. Br J Haematol. 2020;190(5):e279–e282.
    1. Piñana JL, Martino R, García‐García I, Parody R, Morales MD, Benzo G, et al. Risk factors and outcome of COVID‐19 in patients with hematological malignancies. Exp Hematol Oncol. 2020;9:21.
    1. Huff HV, Singh A. Asymptomatic transmission during the COVID‐19 pandemic and implications for public health strategies. Clin Infect Dis. 2020:ciaa654.
    1. PHE . Coronavirus (COVID‐19) in the UK 2020 [updated 03/10/2020]. Available from:
    1. Nikolai LA, Meyer CG, Kremsner PG, Velavan TP. Asymptomatic SARS Coronavirus 2 infection: invisible yet invincible. Int J Infect Dis. 2020;100:112–6.
    1. Aguilar JB, Faust JS, Westafer LM, Gutierrez JB. A Model Describing COVID‐19 Community Transmission Taking into Account Asymptomatic Carriers and Risk Mitigation. medRxiv. 2020; 2020.03.18.20037994.
    1. Zheng S, Fan J, Yu F, Feng B, Lou B, Zou Q, et al. Viral load dynamics and disease severity in patients infected with SARS‐CoV‐2 in Zhejiang province, China, January‐March 2020: retrospective cohort study. BMJ (Clinical research ed). 2020;369:m1443.
    1. Corman VM, Rabenau HF, Adams O, Oberle D, Funk MB, Keller‐Stanislawski B, et al. SARS‐CoV‐2 asymptomatic and symptomatic patients and risk for transfusion transmission. Transfusion. 2020;60(6):1119–22.
    1. Katz LM. Is SARS‐CoV‐2 transfusion transmitted? Transfusion. 2020;60(6):1111–4.
    1. JPAC . Joint UKBTS Professional Advisory Committee: Position statement: SARS‐CoV‐2/COVID‐19 and the safety of Blood, Tissues and Stem Cells. 2020. Available from:
    1. WMDA . Coronavirus ‐ SARS‐CoV‐2 & COVID‐19 2020 [updated 14/08/2020]. Available from:
    1. Medd P, Nagra S, Hollyman D, Craddock C, Malladi R. Cryopreservation of allogeneic PBSC from related and unrelated donors is associated with delayed platelet engraftment but has no impact on survival. Bone Marrow Transplant. 2013;48(2):243–8.
    1. Hamadani M, Zhang MJ, Tang XY, Fei M, Brunstein C, Chhabra S, et al. Graft cryopreservation does not impact overall survival after allogeneic hematopoietic cell transplantation using post‐transplantation cyclophosphamide for graft‐versus‐host disease prophylaxis. Biol Blood Marrow Transplant. 2020;26(7):1312–7.
    1. Ljungman P, Ward KN, Crooks BN, Parker A, Martino R, Shaw PJ, et al. Respiratory virus infections after stem cell transplantation: a prospective study from the Infectious Diseases Working Party of the European Group for Blood and Marrow Transplantation. Bone Marrow Transplant. 2001;28(5):479–84.
    1. Malard F, Genthon A, Brissot E, van de Wyngaert Z, Marjanovic Z, Ikhlef S, et al. COVID‐19 outcomes in patients with hematologic disease. Bone Marrow Transplant. 2020;55:2180–4.
    1. CIBMTR .COVID‐19 Reported Data 2020. Available from:
    1. Rickman HM, Rampling T, Shaw K, Martinez‐Garcia G, Hail L, Coen P, et al. Nosocomial transmission of COVID‐19: a retrospective study of 66 hospital‐acquired cases in a London teaching hospital. Clin Infect Dis. 2020;20:ciaa816.
    1. Rothe C, Schunk M, Sothmann P, Bretzel G, Froeschl G, Wallrauch C, et al. Transmission of 2019‐nCoV infection from an asymptomatic contact in Germany. N Engl J Med. 2020;382(10):970–1.
    1. Afzal A. Molecular diagnostic technologies for COVID‐19: limitations and challenges. J Adv Res. 2020;26:149–59.
    1. Xiao AT, Tong YX, Zhang S. False negative of RT‐PCR and prolonged nucleic acid conversion in COVID‐19: Rather than recurrence. J Med Virol. 2020;92:1755–6.
    1. Cárdenas‐Camarena L, Bayter‐Marin JE, Durán H, Hoyos A, López‐Romero CO, Robles‐Cervantes JA, et al. Elective surgery during SARS‐Cov‐2/COVID‐19 pandemic: safety protocols with literature review. Plast Reconstr Surg. 2020;8(6):e2973.
    1. Gruskay JA, Dvorzhinskiy A, Konnaris MA, LeBrun DG, Ghahramani GC, Premkumar A, et al. Universal testing for COVID‐19 in essential orthopaedic surgery reveals a high percentage of asymptomatic infections. J Bone Joint Surg Am. 2020;102(16):1379–88.
    1. Kader N, Clement ND, Patel VR, Caplan N, Banaszkiewicz P, Kader D. The theoretical mortality risk of an asymptomatic patient with a negative SARS‐CoV‐2 test developing COVID‐19 following elective orthopaedic surgery. Bone Joint J. 2020;102‐b(9):1256–60.
    1. Rivett L, Sridhar S, Sparkes D, Routledge M, Jones NK, Forrest S, et al. Screening of healthcare workers for SARS‐CoV‐2 s the role of asymptomatic carriage in COVID‐19 transmission. eLife. 2020;9:e58728.
    1. CDC . Centre for Disease Control: Interim Guidance on Testing Healthcare Personnel for SARS‐CoV‐2 2020. Available from:
    1. Sorror ML, Maris MB, Storb R, Baron F, Sandmaier BM, Maloney DG, et al. Hematopoietic cell transplantation (HCT)‐specific comorbidity index: a new tool for risk assessment before allogeneic HCT. Blood. 2005;106(8):2912–9.
    1. Sorror ML, Storb RF, Sandmaier BM, Maziarz RT, Pulsipher MA, Maris MB, et al. Comorbidity‐age index: a clinical measure of biologic age before allogeneic hematopoietic cell transplantation. J Clin Oncol. 2014;32(29):3249–56.
    1. Armand P, Kim HT, Logan BR, Wang Z, Alyea EP, Kalaycio ME, et al. Validation and refinement of the Disease Risk Index for allogeneic stem cell transplantation. Blood. 2014;123(23):3664–71.
    1. JACIE . FACT‐JACIE International Standards for Hematopoietic Cellular Therapy. 2018. [updated 01/06/2018]. 7.0. Available from:
    1. Anthony Nolan response to COVID‐19 2020. Available from:

Source: PubMed

Спонсоры и соавторы

Заболевания

Медикаментозные вмешательства

Подписаться